- Home
- NUKK vs SKYE Comparison
NUKK vs SKYE Comparison
Compare NUKK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUKK
- SKYE
- Stock Information
- Founded
- NUKK 2013
- SKYE 2012
- Country
- NUKK United States
- SKYE United States
- Employees
- NUKK N/A
- SKYE N/A
- Industry
- NUKK Blank Checks
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- NUKK Finance
- SKYE Health Care
- Exchange
- NUKK Nasdaq
- SKYE Nasdaq
- Market Cap
- NUKK N/A
- SKYE 80.7M
- IPO Year
- NUKK N/A
- SKYE N/A
- Fundamental
- Price
- NUKK $12.60
- SKYE $1.30
- Analyst Decision
- NUKK
- SKYE Buy
- Analyst Count
- NUKK 0
- SKYE 7
- Target Price
- NUKK N/A
- SKYE $18.00
- AVG Volume (30 Days)
- NUKK 148.1K
- SKYE 238.7K
- Earning Date
- NUKK 05-15-2025
- SKYE 05-09-2025
- Dividend Yield
- NUKK N/A
- SKYE N/A
- EPS Growth
- NUKK N/A
- SKYE N/A
- EPS
- NUKK N/A
- SKYE N/A
- Revenue
- NUKK $5,913,461.00
- SKYE N/A
- Revenue This Year
- NUKK N/A
- SKYE N/A
- Revenue Next Year
- NUKK N/A
- SKYE N/A
- P/E Ratio
- NUKK N/A
- SKYE N/A
- Revenue Growth
- NUKK N/A
- SKYE N/A
- 52 Week Low
- NUKK $1.30
- SKYE $1.22
- 52 Week High
- NUKK $78.32
- SKYE $17.65
- Technical
- Relative Strength Index (RSI)
- NUKK 41.85
- SKYE 27.04
- Support Level
- NUKK $11.08
- SKYE $1.37
- Resistance Level
- NUKK $14.21
- SKYE $2.44
- Average True Range (ATR)
- NUKK 2.07
- SKYE 0.26
- MACD
- NUKK -0.08
- SKYE -0.08
- Stochastic Oscillator
- NUKK 17.46
- SKYE 6.24
Stock Price Comparison Chart: NUKK vs SKYE
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.